title: Fast and Successful Management of Intraocular Inflammation with a Single Intravitreal Dexamethasone Implant.
abstract: Purpose: To investigate the efficacy and safety of a single dexamethasone intravitreal implant (Ozurdex®, 700 µg). Methods: In this prospective noncomparative case series, 84 patients (54 females) received a dexamethasone intravitreal implant. At weeks 4, 12 and 24 after the injection, vitreous haze, macular thickness and best corrected visual acuity (BCVA) were assessed and adverse events reported. Results: Clearance of vitreous haze could be achieved after 4 weeks in 61% of all eyes (p < 0.001) and remained significant until week 24 (p < 0.001). This was paralleled by a reduction of central retinal thickness after 4 (p < 0.001), 12 (p < 0.001) and 24 weeks (p < 0.006). Significant and fast improvement of BCVA was already achieved after 4 weeks (p < 0.001) but vanished by week 24. Intraocular pressure reached ≥35 mm Hg in 3 eyes and was significantly more frequent in intermediate uveitis compared to posterior uveitis (p < 0.016). Conclusions: The dexamethasone implant is effective in controlling intraocular posterior segment inflammation and reduces central retinal thickness fast and effectively. © 2014 S. Karger AG, Basel.
authors.affiliation: Department of Ophthalmology, Campus Virchow-Klinikum, Charité - University Medicine Berlin, Berlin, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Pleyer
authors.forename: Matthias
authors.initials: M
authors.lastname: Klamann
authors.forename: Thierry-Jens
authors.initials: TJ
authors.lastname: Laurent
authors.forename: Martin
authors.initials: M
authors.lastname: Mänz
authors.forename: Dicle
authors.initials: D
authors.lastname: Hazirolan
authors.forename: Sibylle
authors.initials: S
authors.lastname: Winterhalter
authors.forename: Stephan R
authors.initials: SR
authors.lastname: Thurau